MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

Coverage is provided for molecular testing to evaluate or manage suspected hereditary transthyretin amyloidosis (hATTR) when patients have a clinical diagnosis of ATTR, suggestive cardiac features (particularly in African American patients), a first‑degree relative with hATTR, or progressive sensorimotor/autonomic neuropathy with supporting features per guidelines. Coverage requires that testing be clinically actionable (results will inform treatment), the patient was offered genetic counseling, the assay includes guideline‑based minimum genetic content (or a documented known familial single variant), and the test has passed the contractor's technical assessment; assays including potentially harmful additional genetic content are excluded.

"Molecular testing is covered for a patient with a clinical diagnosis of transthyretin amyloidosis (ATTR/hATTR)."

Sign up to see full coverage criteria, indications, and limitations.